Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Divests Its Swine Vaccine Business To Harbin Pharmaceutical Group In China As Condition Of $68 Billion Merger With Wyeth

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Pfizer recently completed the divestment of its swine vaccine business in China to local company Harbin Bio-Vaccine, an animal health subsidiary of Harbin Pharmaceutical Group

You may also be interested in...



Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.

Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.

Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B, Widening Nestle’s Reach In Emerging Markets

Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel